Skip to main content
. 2011 Jun 9;96(10):1441–1447. doi: 10.3324/haematol.2011.046078

Figure 2.

Figure 2.

(A) Overall survival according to treatment response type. (B) Overall survival in patients who achieved mCR with or without HI. P value by landmark analysis with the landmark set at six months from the initial date of decitabine treatment. CR: complete response; PR: partial response; HI: hematologic improvement; SD: stable disease; mCR: marrow complete response; DP: disease progression; NA: not assessable.